source
- Lilly’s retatrutide creeps closer to market for sleep apneaExpectations for the launch of Eli Lilly’s triple agonist retatrutide in obesity, due next year, are at fever pitch. But the company is also lining up data in other indications with the aim of even…Endpoints · 12m ago↗ source
- Biopharma Sentiment Index climbs to upbeat 105 in Q3 2026, marking strongest optimism in yearsEndpoints Signal released its Q3 2026 Biopharma Sentiment Index, showing a dramatic lift in industry mood. The survey indicates the sector is finally in a positive territory after a four-year downt…
- AstraZeneca teams with Oracle on AI-driven clinical trials as FDA clears Haemonetics vascular closure system